Semler Scientific, Inc. filings document its common-stock status, material events and public-company reporting history. Recent regulatory records include Form 25 disclosure for removal of the common stock from Nasdaq listing and registration, and Form 15 certification covering termination or suspension of Exchange Act reporting obligations for the class of securities.
The company's 8-K filings cover material agreements, shareholder voting matters, governance items, capital-structure disclosures and operating and financial results. Filing categories also address risk factors and clinical or regulatory matters tied to Semler Scientific's healthcare technology activities, alongside disclosures related to its Bitcoin treasury strategy.
Semler Scientific, Inc. (SMLR) has called its 2025 virtual Annual Meeting for September 5, 2025. The proxy outlines six voting items, with management emphasizing Proposals 3 and 4, which would:
- Increase authorized common stock to 210 million shares (from 50 million).
- Create 42 million shares of “blank-check” preferred stock.
Management argues that the additional capital flexibility is critical to funding the company’s dual strategy:
- Bitcoin treasury program – Adopted May 2024; holdings now 4,636 BTC worth $508 million (7/2/2025). BTC yield since adoption: 294%. Share price up 69% versus 17% for the S&P 500.
- Healthcare expansion – Launch of wholly owned subsidiary CardioVanta™ (June 2025) focusing on SaaS-based early heart-failure and arrhythmia detection, while QuantaFlo® continues to address peripheral artery disease.
Long-term BTC accumulation targets are ambitious: 10,000 BTC by YE 2025, 42,000 BTC by YE 2026, and 105,000 BTC by YE 2027. The company has funded BTC purchases through operating cash flow, equity sales, convertible debt, and asset monetization.
Director & governance highlights: One Class I director (William H.C. Chang) stands for reelection. Natalie Brunell and Joe Burnett were added in 2025 to deepen Bitcoin expertise. A new Bitcoin Strategy Committee oversees treasury activities. Three directors remain Nasdaq-independent.
Capital structure context: As of 6/30/2025, 13.69 million shares are outstanding with ~31.16 million unreserved. Outstanding 4.25% convertible notes due 2030 could add up to 1.64 million shares at a $76.44 conversion price. Management warns the current share limit could impede future fundraising and employee incentives.
Other proposals: advisory say-on-pay, auditor ratification (BDO USA, P.C.), and routine meeting matters.
Key considerations for investors: while the Bitcoin strategy has boosted returns, issuing up to 160 million additional common shares and 42 million preferred shares could materially dilute existing holders and provide management with anti-takeover tools. Conversely, rejection could constrain growth capital and BTC accumulation plans.
Semler Scientific, Inc. (SMLR) – Form 4 Overview
Director Natalie Brunell reported the grant of a single derivative security on 25 June 2025. The filing covers a stock option to purchase 1,125 shares of common stock at an exercise price of $41.04 per share. The instrument is classified as an acquisition (transaction code “A”).
Vesting schedule: 1/6 of the option (≈188 shares) vested immediately on the grant date, with the remaining 5/6 vesting in equal monthly tranches, resulting in full vesting six months after 25 June 2025. The option expires on 25 June 2035.
Post-transaction holdings: Ms. Brunell now beneficially owns 1,125 derivative securities directly. No non-derivative (outright share) transactions were reported.
No 10b5-1 trading plan was indicated, and no other insider participated in this filing. The grant appears to be a routine director compensation award and does not include any immediately exercisable common-stock sales or purchases.
Semler Scientific (Nasdaq:SMLR) filed a Form 8-K to report that on June 22, 2025 its board adopted Fifth Amended and Restated Bylaws, effective immediately.
According to Item 5.03, the revisions are limited to two governance housekeeping items: (i) removal of Section 13 to eliminate any ambiguity with Delaware General Corporation Law §228 (shareholder written consents) and (ii) revision of Section 47 so that the bylaws fully harmonize with the company’s certificate of incorporation. No changes were made to the fiscal year, capital structure, or shareholder voting thresholds.
The full text of the updated bylaws is provided as Exhibit 3.1. Other than the technical governance clean-up, the filing contains no financial statements, forward-looking guidance, or other material events. The document was signed by Chief Financial Officer Renae Cormier on June 23, 2025.
Semler Scientific, Inc. (Nasdaq: SMLR) filed an 8-K to disclose a major shift in its treasury policy. On 19 June 2025 the company appointed Joe Burnett as Director of Bitcoin Strategy and outlined an aggressive three-year plan to accumulate Bitcoin using a combination of equity offerings, debt financings and operating cash flow.
- Accumulation targets: at least 10,000 BTC by 31-Dec-2025, 42,000 BTC by 31-Dec-2026 and 105,000 BTC by 31-Dec-2027.
- Funding sources: prospective sales of securities, borrowings and internal cash generation.
- Governance: Burnett will oversee execution and risk management of the Bitcoin treasury strategy.
The filing contains extensive forward-looking statements highlighting material risks, including Bitcoin price volatility, execution risk in raising capital, leverage concerns and uncertainties related to the company’s proposed DOJ settlement. Management makes no commitment to update projections.
Investment view: The move could materially increase balance-sheet optionality if Bitcoin appreciates, but exposes shareholders to significant market and financing risk. The 8-K carries no immediate financial results or guidance changes.